A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
Recruiting now · Phase 1
Conditions studied: Glioblastoma Multiforme of Brain, Glioma, Glioblastoma
In brief
This is an open-label, multicenter dose-escalation study to be followed by a dose expansion to define the optimal dose of GLIX1 as monotherapy by reviewing safety and tolerability, disease characteristics and pharmacokinetic profiles and preliminary clinical activity in participants with a high grade diffuse glioma that progressed during or recurred after prior standard of care therapies or investigational therapies as clinically indicated. Patients will be treated daily with GLIX1 capsules until disease progression or unacceptable safety.
Key facts
- Study ID
- NCT07464925
- Run by
- Tetragon Biosciences Ltd
- People needed
- 30
- Starts
- 2026-04-20
- Expected to finish
- 2027-12-01
- Last updated by the study team
- 2026-07-30
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Moffitt Cancer Center — Tampa, Florida, United States (enrolling)
- Northwestern Medicine — Chicago, Illinois, United States (enrolling)
- NYU Langone Health — New York, New York, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.